Skip to main content

Table 1 Surviving fraction and micronucleus frequency at 0 Gy

From: The dependency of compound biological effectiveness factors on the type and the concentration of administered neutron capture agents in boron neutron capture therapy

 

Total tumor cells

Quiescent cells

<Plating efficiency (%)>

  

Without 10B-carrier

70.7 ± 8.8a

----

BPAb (250 mg/kg)

45.5 ± 5.8

----

BPA (500 mg/kg)

40.5 ± 4.6

----

BPA (750 mg/kg)

39.4 ± 3.8

----

BSHc (125 mg/kg)

54.0 ± 6.8

----

BSH (250 mg/kg)

50.0 ± 5.8

----

BSH (325 mg/kg)

44.8 ± 4.8

----

<Micronucleus frequency>

  

Without 10B-carrier

0.029 ± 0.007

0.053 ± 0.007

BPA (250 mg/kg)

0.045 ± 0.010

0.067 ± 0.008

BPA (500 mg/kg)

0.050 ± 0.011

0.073 ± 0.009

BPA (750 mg/kg)

0.054 ± 0.012

0.078 ± 0.012

BSH (125 mg/kg)

0.042 ± 0.005

0.069 ± 0.011

BSH (250 mg/kg)

0.047 ± 0.005

0.075 ± 0.010

BSH (325 mg/kg)

0.052 ± 0.007

0.081 ± 0.012

  1. a; Mean ± standard error (n = 9).
  2. b; Boronophenylalanine-10B.
  3. c; Sodium mercaptododecaborate-10B.
  4. The values of the plating efficiencies and micronucleus frequencies for the combination with the 10B-carrier were significantly lower and higher than those for no combination with the 10B-carrier, respectively.
  5. The values of the micronucleus frequencies for quiescent cells were significantly higher than those for total tumor cells.